If you need more lookups,
subscriptions start at $34 USD/month.
Robert Drakas Location
Philadelphia, PA, US
Robert Drakas Work
2025 -now Chief Business Officer @
2021 -2025 Co-founding CEO and Director @
2019 -2025 Board Observer @
2022 -2025 President @ ShangPharma Innovation
2020 -2025 Board Member @ ShangPharma Innovation
2021 -2025 Board Member @
2020 -2021 Vice President @ ShangPharma Innovation
2016 -2020 Executive Director @ ShangPharma Innovation
2019 -2021 Board Observer @
2020 -2024 Board Member @ Blue Oak Therapeutics
2017 -2019 Board Observer @ Tilos Therapeutics
2012 -2017 Senior Director Business Development @ ChemPartner Inc. USA
2016 -2016 Executive Director ShangPharma Investment Group @ ShangPharma
2007 -2011 Senior Analyst @
2004 -2007 Senior Research Biochemist @
2000 -2004 Senior Biochemist @
1995 -2000 Biochemist @
Robert Drakas Education
Thomas Jefferson University
PhD (Molecular Pharmacology)
Drexel University
M.S. Biological Sciences (Biochemistry)
University of Scranton
Bachelor of Science (BS) (Biology, General)
Robert Drakas Skills
Lifesciences
Drug Discovery
Biotechnology
Drug Development
Oncology
CRO
Pharmaceutical Industry
Assay Development
In Vitro
Cancer
Molecular Biology
Cell Biology
Immunology
GLP
Clinical Trials
Technology Transfer
Clinical Development
Pharmacology
Biomarkers
High Throughput Screening
Medicinal Chemistry
Life Sciences
Public Speaking
Strategy
Microsoft Office
High Throughput
Microsoft Excel
Leadership
Biochemistry
Robert Drakas Summary
Robert Drakas, based in Philadelphia, PA, US, is currently a Chief Business Officer at Evrys Bio. Robert Drakas brings experience from previous roles at Rila Therapeutics, Evrys Bio and ShangPharma Innovation. Robert Drakas holds a PhD in Molecular Pharmacology @ Thomas Jefferson University. With a robust skill set that includes Lifesciences, Drug Discovery, Biotechnology, Drug Development, Oncology and more. Robert Drakas has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Robert Drakas?
Find contact details for 700 million professionals.